PMID- 26288408
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150820
LR  - 20181113
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Print)
IS  - 0019-5154 (Linking)
VI  - 60
IP  - 4
DP  - 2015 Jul-Aug
TI  - Omalizumab-A Review.
PG  - 381-4
LID - 10.4103/0019-5154.160490 [doi]
AB  - Omalizumab is a recombinant, humanized, monoclonal antibody against human 
      immunoglobulin E (IgE). The US FDA has approved this molecule for chronic 
      urticaria.
FAU - Godse, Kiran
AU  - Godse K
AD  - Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, 
      Navi Mumbai, India.
FAU - Mehta, Aayushi
AU  - Mehta A
AD  - Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, 
      Navi Mumbai, India.
FAU - Patil, Sharmila
AU  - Patil S
AD  - Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, 
      Navi Mumbai, India.
FAU - Gautam, Manjyot
AU  - Gautam M
AD  - Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, 
      Navi Mumbai, India.
FAU - Nadkarni, Nitin
AU  - Nadkarni N
AD  - Department of Dermatology, Dr. D. Y. Patil Medical College and Hospital, Nerul, 
      Navi Mumbai, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC4533538
OTO - NOTNLM
OT  - Anaphylaxis
OT  - FDA approval
OT  - atopic dermatitis
OT  - chronic urticaria
OT  - monoclonal antibody
COIS- Conflict of Interest: Nil.
EDAT- 2015/08/20 06:00
MHDA- 2015/08/20 06:01
PMCR- 2015/07/01
CRDT- 2015/08/20 06:00
PHST- 2015/08/20 06:00 [entrez]
PHST- 2015/08/20 06:00 [pubmed]
PHST- 2015/08/20 06:01 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - IJD-60-381 [pii]
AID - 10.4103/0019-5154.160490 [doi]
PST - ppublish
SO  - Indian J Dermatol. 2015 Jul-Aug;60(4):381-4. doi: 10.4103/0019-5154.160490.